YQ could attenuate type 2 diabetes mellitus by improving ß-cell via IRS-2/AKT/GLUT4 pathway and NAFLD by ameliorating lipid accumulation via AMPKα/ACC1/PPARα/SREBP1 pathway (Figure 13). This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.